MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?
Authors:
- 25 May 2022
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 108, 108863
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- Development of a Unique Small Molecule Modulator of CXCR4PLOS ONE, 2012
- Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cellsJournal of Translational Medicine, 2012
- CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell MigrationJournal of Biological Chemistry, 2011
- MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemiasBlood Cancer Journal, 2011
- SIRT3 Controls Cancer Metabolic Reprogramming by Regulating ROS and HIFCancer Cell, 2011
- Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor GrowthCancer Cell, 2011
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide AntagonistsScience, 2010
- CXCR4-Mediated Bone Marrow Progenitor Cell Maintenance and Mobilization Are Modulated by c-kit ActivityCirculation Research, 2010
- Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF- B pathways and promotes osteoclastogenesis in human oral cancer cellsCarcinogenesis, 2008
- Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epitheliaLaboratory Investigation, 2007